Imovax d.T. Special Precautions

As with all vaccinations, in the event of an allergic reaction following vaccination, appropriate medical treatment must be available for immediate treatment and adequate monitoring must be carried out.
To reduce the severity of adverse reactions, avoid administering the vaccine to persons who have received a complete primary vaccination or a booster vaccination in the previous 5 years. As with other intramuscular injections, the vaccine should be given with caution in subjects receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these vaccines.
Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection, except in case of a tetanus-prone wound. The presence of a minor infection and/or low-grade fever should not delay vaccination.
If Guillain-Barré syndrome or plexus brachialis neuritis has occurred after a previous administration of a tetanus vaccine, the decision to give any vaccine containing tetanus toxoid should be based on careful consideration of the potential benefits and possible risks.
Antibody formation may be impaired during immunosuppressive treatment or in patients who suffer from weakened immune function. In these cases, vaccination should be deferred until therapy is completed or the antibody titer is checked. Nevertheless, in individuals with chronic immunodeficiency disease, such as HIV infection, vaccination is recommended if the course of the disease allows a reduced triggering of the antibody response.
Syncope can occur following, or even before, administration of injectable vaccines, including Imovax d.T. Procedures should be in place to prevent falling injury and manage syncopal reactions.
As with any vaccine, vaccination with Imovax d.T. may not protect all vaccine recipients.
Imovax d.T. contains less than 1 mmol (39 mg) of potassium and less than 1 mmol (23 mg) of sodium per dose, that is to say essentially "potassium-free" and "sodium-free".
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Effects on ability to drive and use machines: Imovax d.T. has no or a negligible effect on the ability to drive and operate machinery.